Target: A specific identifier (protein glycoprotein, or carbohydrate) found on a cancer or group of cancers. This identifier becomes the imaging and therapeutic target for the radiopharmaceutical ligand. Targets that are currently being investigated for various cancers are listed below.

Targets


17β-estradiol

  • Breast

ACE-2

  • Lung

Amino Acid Transport

  • Prostate (GU)
  • Brain and Central Nervous System (CNS)
  • Pituitary

B7H3

  • Pancreatic (GI)
  • Hepatocellular/Liver (GI)

CAIX

  • Kidney/Renal Cell Carcinoma (GU)
  • Breast
  • General Solid Tumors (Multiple Types)
  • Colon/Rectal/Anal (GI)

CAXll

  • Brain and Central Nervous System (CNS)

CCR2

  • Head and Neck Cancers

CD25

  • Leukemias

CD44v6

  • Head and Neck Cancers
  • Lung
  • Gynecologic (GYN) (Multiple Types)
  • Cervical (GYN)
  • Thyroid

CD45

  • Leukemias

CD70

  • Kidney/Renal Cell Carcinoma (GU)
  • Lymphomas

CD8 Cells

  • Kidney/Renal Cell Carcinoma (GU)
  • Melanoma/Skin Cancers

CEA

  • Colon/Rectal/Anal (GI)

Cholecystokinin-2 (CCK2R)

  • Lung

Chondroitin Sulfate

  • Sarcoma
  • Bladder/Urothelial (GU)
  • Colon/Rectal/Anal (GI)
  • Pancreatic (GI)
  • Lung

Claudin 18.2

  • Pancreatic (GI)
  • Gastric/Stomach (GI)
  • Gastrointestinal (GI) (Multiple Types)

CXCR4

  • Breast
  • Multiple Myeloma
  • Thymoma

Cystine/glutamate antiporter

  • Esophageal (GI)

DLL3

  • NeuroEndocrine Carcinoma (NEC)
  • Lung

EGFR-cMET

  • Lung

Estrogen Receptor

  • Breast

FAP

  • Breast
  • NeuroEndocrine Carcinoma (NEC)
  • Sarcoma
  • Ovarian/Primary Peritoneal (GYN)
  • General Solid Tumors (Multiple Types)

FR (Folate Receptor)

  • Osteosarcoma
  • Bone Metastases

FSPG

  • Esophageal (GI)

GD2

  • Lung

Glucose Transport

  • Kidney/Renal Cell Carcinoma (GU)
  • Breast
  • Leukemias
  • Prostate (GU)
  • NeuroEndocrine Carcinoma (NEC)

GPC3

  • Hepatocellular/Liver (GI)

Granzyme B

  • Pancreatic (GI)
  • Hepatocellular/Liver (GI)
  • Gastrointestinal (GI) (Multiple Types)

GrB (GRIP-B)

  • Kidney/Renal Cell Carcinoma (GU)
  • General Solid Tumors (Multiple Types)
  • Bladder/Urothelial (GU)

GRPR

  • Breast
  • Prostate (GU)
  • General Solid Tumors (Multiple Types)
  • Colon/Rectal/Anal (GI)
  • Lung

HER2

  • Breast
  • Esophageal (GI)
  • Gastric/Stomach (GI)

HK2

  • Prostate (GU)

IGF-1R

  • Breast
  • Prostate (GU)
  • General Solid Tumors (Multiple Types)
  • Head and Neck Cancers
  • Ovarian

LAG3

  • General Solid Tumors (Multiple Types)

LAT1/LAT2

  • Brain and Central Nervous System (CNS)

MC1R

  • Melanoma/Skin Cancers

MC2R

  • Adrenal Gland/Adrenocortical

Nectin-4

  • Bladder/Urothelial (GU)

NET

  • Pheochromocytoma (NEC)
  • Paraganglioma (NEC)

NTSR-1

  • Head and Neck Cancers

O-(2-[18F]-fluoroethyl)-L-tyrosine (FET)

  • Brain and Central Nervous System (CNS)

PARP

  • Breast
  • Prostate (GU)
  • NeuroEndocrine Carcinoma (NEC)
  • Ovarian/Primary Peritoneal (GYN)

PD-L1

  • Lung

PSMA

  • Kidney/Renal Cell Carcinoma (GU)
  • Prostate (GU)
  • Adrenal Gland/Adrenocortical
  • Brain and Central Nervous System (CNS)
  • Hepatocellular/Liver (GI)

SSTR+

  • NeuroEndocrine Carcinoma (NEC)
  • Head and Neck Cancers
  • Lung

SSTR1

  • Brain and Central Nervous System (CNS)

SSTR2

  • NeuroBlastoma

SSTR3

  • NeuroEndocrine Carcinoma (NEC)

Trop-2

  • Prostate (GU)

uPAR

  • Breast

αvβ3

  • NeuroEndocrine Carcinoma (NEC)
  • General Solid Tumors (Multiple Types)
  • Pancreatic (GI)
  • Brain and Central Nervous System (CNS)
  • Esophageal (GI)

αvβ5

  • General Solid Tumors (Multiple Types)
  • Pancreatic (GI)
  • Esophageal (GI)

αvβ6

  • Pancreatic (GI)
  • Lung

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468